IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Hakomori & Handa.

Appl. No.: 10/669,264

Conf. No.: 3225

Filed: September 25, 2003

Title: CANCER-ASSOCIATED CARBOHYDRATE VACCINES

Art Unit: 1645 Examiner: S. Devi Docket No.: 116653-017

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

Sir:

Submitted herewith is an Information Disclosure Statement for consideration in the above-identified application. In accordance with the provisions of 37 C.F.R. 1.56, 37 C.F.R. 1.97, and 37 C.F.R. 1.98, Applicants request that a citation and examination of the references cited on the enclosed PTO-1449 form be made during the course of examination of the above-identified application for United States patent. Pursuant to 37 C.F.R. 1.98, copies of any cited foreign patent documents and non-patent documents are enclosed.

This Information Disclosure Statement is submitted:

[X]	Within three months of filing of a national application; within three months of the
	date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an
	international application; before the mailing date of a first Office Action on the
	merits, or before the mailing of a first Office Action after the filing of a Request
	for Continued Examination.

[]	under	the period specified above, but before the mailing date of a Final Action 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action herwise closes prosecution in the application and is accompanied by one of:
	[]	Payment of the fee set forth in 37 CFR 1.17(p); or

[] The certification specified in 37 CFR 1.97(e) follows.

[] After the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application and is accompanied by the fee set forth in 37 CFR 1.17(p) and the certification specified in 37 CFR 1.97(e) follows.

106900/F/1 1

- The undersigned counsel for applicant(s) hereby certifies each item of information contained in the accompanying Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement.
 The undersigned counsel for applicant(s) hereby certifies that no item of information contained in the accompanying Information Disclosure Statement.
- [] The undersigned counsel for applicant(s) hereby certifies that no item of information contained in the accompanying Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.
- [] A copy of a Search Report from a corresponding foreign patent application is enclosed.
- [] A check in the amount of \$180 to cover the required fee is enclosed.
- [] The Commissioner is hereby authorized to charge the amount of \$180 to cover the required fee to Deposit Account No. 02-1818.
- [X] The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 02-1818.

2

Respectfully submitted,

BELL BOYD & PROYD LLP

BY Well

Dean H. Nakamura Reg. No. 33981 Customer No. 29180

Dated: 9 July 2007

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)
PTO Form 1449

-	A 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10	Ta transfer No.
		Application No.
	116653-017	10/669,264
	Applicant	Date Submitted
	Hakomori et al.	July 9, 2007
	Filing Date	Group
	September 25, 2003	1645

Examiner's Initials	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	Ito, et al., "Specificity and Immunobiological Properties of Monoclonal Antibody IMH2, Established after Immunization with Le ^b /Le ^c Glycosphingolipid, a Novel Extended Type 1 Chain Antigen, "Cancer Research S2, July 1, 1992, pp. 3739-3745
	Stroud, et al., "Extended Type I Chain Glycosphingolipids: Dimeric Le' (III "V"Fuc ₂ Lc ₂) as Human Tumor-associated Antigen," <i>The Journal of Biological Chemistry</i> , Vol. 266, No. 13, May 5, 1991, pp. 8439-8446
-	

Examiner:	Date Considered:
*Examiner: Initial if citation considered, whether or not	citation is in conformance with MPEP Section 609;
Draw line through citation if not in conformance and no	ot considered. Include copy of this form with next
communication to applicant	

106904/F/1